Search the Newsreel

Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $30.00

Mizuho has raised its price target for Amylyx Pharmaceuticals (NASDAQ:AMLX) to $30.00 from $24.00, maintaining an "outperform" rating, indicating a potential 38.7% upside. Despite this, the company reported a quarterly loss of $0.39 per share, missing analyst estimates. Institutional investors and hedge funds hold …

EYPT Looks 4000.0% Overvalued on GF Value™

EyePoint Pharmaceuticals (EYPT) is considered 4000.0% overvalued based on GuruFocus's GF Value™ metric, trading at $14.76 against an estimated fair value of $0.36. This extreme valuation comes despite its Duravyu wet AMD trial showing mixed results—failing the primary endpoint in the overall dataset but …

Alpha Cognition (ACOG) Stock Fair Value Rises After Zunveyl Analyst Optimism

Alpha Cognition's (ACOG) fair value price target has increased from US$14.67 to US$16.75, attributed to analyst optimism surrounding its drug Zunveyl. Analysts highlight strong Q2 results, improving commercial execution, positive payer discussions, and Zunveyl's potential to address tolerability issues in Alzheimer's treatment. While bullish …

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

Rhythm Pharmaceuticals, Inc. BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the appointment of Manher "AJ" Joshi, M.D., as Chief Medical …

ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $47.00

HC Wainwright has increased its price target for ArriVent BioPharma (NASDAQ:AVBP) to $47.00 from $44.00, maintaining a "buy" rating and implying a 59% upside. This comes amidst a generally positive analyst sentiment, with eight analysts rating the stock a "Buy," one a "Hold," and …

Monaco Asset Management SAM Invests $8.48 Million in Rocket Pharmaceuticals, Inc. $RCKT

Monaco Asset Management SAM has acquired a new stake worth $8.48 million in Rocket Pharmaceuticals (NASDAQ: RCKT), making it the firm's 11th largest holding and representing 2.27% of the biotechnology company's shares. Despite institutional investors owning 98.39% of the stock and the company beating …

Radiopharm schedules FDA meeting for brain imaging agent RAD101 By Investing.com

Radiopharm Theranostics has scheduled an End-of-Phase 2 meeting with the FDA for October 1, 2026, to discuss the Phase 3 trial design for its brain imaging agent, RAD101. RAD101, which has FDA Fast Track Designation, is developed to diagnose recurrent brain metastases and showed …

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

Radiopharm Theranostics is scheduled to meet with the U.S. FDA on October 1st, 2026, for an End-of-Phase 2 meeting to discuss the pivotal Phase 3 trial design for RAD101. This imaging agent, which targets fatty acid synthase (FASN), is being developed for the diagnosis …

A PET scan matched MRI in 93% of lesions—what comes next?

Radiopharm Theranostics has scheduled an End-of-Phase 2 meeting with the U.S. FDA for October 1, 2026, to discuss the pivotal Phase 3 trial design for RAD101, an imaging agent for recurrent brain metastases. The company's Phase 2b trial showed a 93% concordance between MRI …

NRX Pharmaceuticals reports $18.0M net loss for first half 2026, $26.7M cash on hand

NRX Pharmaceuticals reported a net loss of $18.0 million for the first half of 2026, with an operating loss widening to $11.3 million. The company holds $26.7 million in cash and expects current resources, revenue growth, and an at-the-market facility to fund operations for …

Hyphens Pharma Lifts Margins and Profit as Portfolio Revamp Takes Hold

Weekly Recap: Large revaluation gains and $811B off-balance commitments

Alphabet Inc. (GOOG) reported significant Q2 GAAP EPS driven by $98 billion in unrealized revaluation gains, while also revealing a massive $811 billion in long-term off-balance-sheet purchase commitments. The company is undergoing major AI leadership changes, with Gemini now reaching one billion users, and …

Kelun-Biotech Announces 2026 Interim Results

CHENGDU, China, Aug. 17, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", Stock Code: 6990.HK) announces its unaudited consolidated results for the period ended 30 June 2026 (the "Reporting Period"). Key information is as follows: Revenue amounted to approximately RMB …

Persistent Asset Partners Ltd Makes New $4.57 Million Investment in BioMarin Pharmaceutical Inc. $BMRN

Persistent Asset Partners Ltd has made a new investment of $4.57 million in BioMarin Pharmaceutical Inc., acquiring 79,933 shares, which now constitutes 1.4% of its portfolio. BioMarin recently reported strong Q2 earnings, surpassing analyst estimates with $1.20 EPS and $989.71 million in revenue, and …

Monaco Asset Management SAM Invests $10.58 Million in BioMarin Pharmaceutical Inc. $BMRN

Monaco Asset Management SAM has invested $10.58 million in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), acquiring 184,937 shares, making it their eighth-largest holding. This investment comes as BioMarin reported strong quarterly earnings, beating analyst estimates with $1.20 EPS and a 20% revenue increase year-over-year. Analysts generally …

A Coating About Two Sheets Thick Reduced Microwave Interference—Can It Scale?

Zentek (NASDAQ: ZTEK) has filed a provisional patent application for ZEN-EMI-01, a water-based electromagnetic interference (EMI) shielding coating made from purified graphite from its Albany deposit. Internal lab tests showed that a thin layer of this coating significantly reduced microwave frequencies used in radar …

UBS raises Acadia Pharmaceuticals stock price target on trial optimism

UBS has increased its price target for Acadia Pharmaceuticals (NASDAQ: ACAD) to $49 from $45, maintaining a Buy rating, due to increased optimism for its drug remlifanserin in Alzheimer’s disease psychosis. The firm raised its probability of success for remlifanserin to 50% and its …

Alphabet eyes inaugural Australian dollar bond, bookrunner’s message says By Reuters

Alphabet is reportedly planning its first Australian dollar bond issue, with investment banks mandated to arrange the transaction. The U.S. tech giant is considering issuing 3-, 5-, 10-, and 20-year bonds, with the proceeds likely supporting its substantial AI spending, which led to negative …

Mizuho raises Amylyx stock price target to $30 on higher pricing

Mizuho has increased its price target for Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) shares to $30 from $24, while maintaining an Outperform rating, due to updated pricing assumptions for its lead asset, avexitide. The firm anticipates positive Phase 3 LUCIDITY study data for avexitide in late …

Phillips Edison & Co Inc's Dividend Analysis

This article first appeared on GuruFocus. Assessing the Upcoming Payout and Long-Term Sustainability Phillips Edison & Co Inc (NASDAQ:PECO) recently announced a total dividend of $0.11 per share, with the ex-dividend date set for 2026-08-17. This includes a $0.11 per share cash dividend payable …

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter

NRx Pharmaceuticals reported its second-quarter 2026 financial results, highlighting significant progress in advancing its preservative-free ketamine ANDA towards FDA approval and commercialization. The company secured $22.3 million in gross proceeds from a public offering, ensuring over a year of operations, and expanded its clinical …

EyePoint’s DURAVYU misses primary endpoint in wet AMD trial

EyePoint, Inc. announced that its Phase 3 LUGANO trial for DURAVYU in wet AMD treatment failed to meet its primary endpoint, largely due to an asymmetric cohort of patients experiencing vision loss unrelated to wet AMD. Despite this, an ad hoc analysis showed non-inferiority …

ConocoPhillips's Dividend Analysis

This article first appeared on GuruFocus. Assessing the Upcoming Payout and Long-Term Sustainability ConocoPhillips (NYSE:COP) recently announced a total dividend of $0.84 per share, with the ex-dividend date set for 2026-08-17. This payment includes a $0.84 per share cash dividend, payable on 2026-09-01. As …

From Hikma Pharmaceuticals (LSE:HIK) To Spire Healthcare Group (LSE:SPI): What Is Separating Healthcare Stocks Today?

Which part of the Poolbeg Pharma (LSE:POLB) immunotherapy story is driving UK small-cap interest today?

Aarey Drugs Q1 Results: Revenue up 145% YoY, net profit falls 60%

Which Pressures Are Holding Back Smith & Nephew (LSE:SN.) And ConvaTec (LSE:CTEC) Right Now?

Traws Pharma beats Q2 loss estimates, shares jump 4%

AIGH Capital Management LLC Purchases New Stake in Vanda Pharmaceuticals Inc. $VNDA

AIGH Capital Management LLC has acquired a new stake of over 2 million shares in Vanda Pharmaceuticals Inc., valued at approximately $12.5 million, making it their 21st largest position. Analyst sentiment for Vanda Pharmaceuticals is mixed but leans positive, with a "Moderate Buy" consensus …

Monaco Asset Management SAM Invests $1.35 Million in Vanda Pharmaceuticals Inc. $VNDA

Monaco Asset Management SAM has acquired a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), purchasing 221,286 shares valued at approximately $1.35 million. This investment makes Vanda Pharmaceuticals 0.1% of Monaco Asset Management SAM's portfolio and represents about 0.37% ownership of the company. The biopharmaceutical …

Murphy Oil Corp's Dividend Analysis

This article first appeared on GuruFocus. Assessing the Sustainability and Growth of Murphy Oil's Quarterly Payout Murphy Oil Corp (NYSE:MUR) recently announced a total dividend of $0.35 per share, with the ex-dividend date set for 2026-08-17. This includes a $0.35 per share cash dividend …

Simplicity Wealth LLC Takes Position in Parker-Hannifin Corporation $PH

Simplicity Wealth LLC has acquired a new stake in Parker-Hannifin Corporation (NYSE:PH), purchasing 959 shares valued at approximately $938,000. This move aligns with several other institutional investors who have recently adjusted their positions in the industrial products company. Parker-Hannifin has also received positive analyst …

Broker Revenue Forecasts For Sutro Biopharma, Inc. (NASDAQ:STRO) Are Surging Higher

2,582 Shares in Parker-Hannifin Corporation $PH Acquired by Roman Butler Fullerton & Co.

Roman Butler Fullerton & Co. has acquired a new stake of 2,582 shares in Parker-Hannifin Corporation (NYSE:PH), valued at approximately $2,456,000. This comes as several other institutional investors also adjusted their holdings in the industrial products company. Parker-Hannifin recently reported strong earnings, beating analyst …

2,792 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by Simplicity Wealth LLC

Simplicity Wealth LLC recently acquired 2,792 shares of Vertex Pharmaceuticals (NASDAQ:VRTX) valued at approximately $1.39 million during the second quarter. Vertex reported quarterly revenue of $3.33 billion, exceeding estimates, though its EPS of $4.73 narrowly missed consensus. The company holds a "Moderate Buy" rating …

Plato Investment Management Ltd Purchases Shares of 6,083 Vertex Pharmaceuticals Incorporated $VRTX

Plato Investment Management Ltd recently acquired 6,083 shares of Vertex Pharmaceuticals (NASDAQ:VRTX) valued at approximately $3 million during the second quarter. Other institutional investors have also increased their holdings, leading to institutions collectively owning 90.96% of the company's stock. Despite some insider selling, analysts …